

30 June 2023

**Hemogenyx Pharmaceuticals plc**  
("Hemogenyx Pharmaceuticals" or the "Company")

**Result of Annual General Meeting**

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed on a show of hands. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.

**Proxy Voting Results**

Ordinary Resolutions	Votes for	% of votes cast for	Votes Against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes with-held (2)
1. To adopt the 2022 Annual Report and Accounts	187,231,295	99.86	260,529	0.14	187,491,824	16.42	4,905,675
2. To approve the Directors' Remuneration Policy	175,511,893	91.34	16,644,001	8.66	192,155,894	16.83	241,605
3. To re-appoint Peter Redmond as Director	161,957,826	86.38	25,531,232	13.62	187,489,058	16.42	4,908,441
4. To re-appoint Alexis Sandler as Director	175,078,447	93.44	12,285,451	6.56	187,363,898	16.41	5,033,601
5. To re-appoint Dr Vladislav Sandler as Director	175,160,284	93.49	12,203,614	6.51	187,363,898	16.41	5,033,601
6. To reappoint the Company's auditor	185,776,647	99.09	1,715,177	0.91	187,491,824	16.42	4,905,675
7. To authorise the Audit Committee to determine the auditor's remuneration	176,309,143	94.04	11,179,915	5.96	187,489,058	16.42%	4,908,441
8. To authorise the Directors to allot equity securities	170,229,487	90.79	17,259,571	9.21	187,489,058	16.42	4,908,441
Special Resolutions	Votes for	% of votes cast for	Votes against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes with-held (2)
9. To disapply pre-emption provisions	156,025,169	89.79	17,751,132	10.21	173,776,301	15.22	18,621,198
10. To reduce the notice period for general meetings	171,582,521	91.51	15,909,303	8.49	187,491,824	16.42	4,905,675

- (1) The Company's issued share capital ("ISC") on 28 June 2023, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 1,141,999,321 ordinary shares.
- (2) A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>

**Enquiries:**

**Hemogenyx Pharmaceuticals plc**

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

Peter Redmond, Director

<https://hemogenyx.com>

[headquarters@hemogenyx.com](mailto:headquarters@hemogenyx.com)

[peter.redmond@hemogenyx.com](mailto:peter.redmond@hemogenyx.com)

**SP Angel Corporate Finance LLP**

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Adam Cowl

**Peterhouse Capital Limited**

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lse.com](mailto:ms@lse.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGNKKBKPBKDAAN